An AllTrials project

NCT04669067: An ongoing trial by Telios Pharma, Inc.

This trial is ongoing. It must report results 4 months, 2 weeks from now.

Full data

Full entry on ClinicalTrials.gov NCT04669067
Title An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date March 31, 2021
Completion date Nov. 30, 2024
Required reporting date Nov. 30, 2025, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov July 16, 2025
Days late None